latest update:
[TrialBase DB]

trial summary · NCT07444541

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Trial record from the TrialBase DB dataset, status RECRUITING, condition Pancreatic Cancer, sponsored by Anova Innovation Limited. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07444541phase PHASE1/PHASE2enrollment 84start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.

Source record: https://clinicaltrials.gov/study/NCT07444541

Facts

registry idNCT07444541
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionPancreatic Cancer
sponsorAnova Innovation Limited
sponsor classINDUSTRY
enrollment84
start date2026-12
primary completion2027-08
completion2028-12
results postednot reported

Conditions

  • Pancreatic Cancer

Interventions

  • ANO31905
  • AG [gemcitabine+nab-paclitaxel]
  • mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]

Countries

  • United States

Intervention types: DRUG

Work with this record